Tuesday

BioTech Webinars

Oct. 27th

1

11:00 am – 12:00 pm ET

Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions?

Category: Chronic conditions

Michael_Rosenblatt

Chair:
Dr. Michael Rosenblatt, MD

Chief Medical Officer
Flagship Pioneering, Cambridge, MA

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Jessica_Grossman_Medicines360_BioTech_Web_1

Jessica Grossman, MD
CEO
Medicines360

 

> More about the product

Liletta_logo
Ponda_Motsepe_Ditshego_Amgen_BioTech_Web_1

Ponda Motsepe – Ditshego, MD
Executive Medical Director
Amgen Bone

 

> More about the product

Evenity_logo
Xu_Cen_Amgen_BioTech_Web_1

Cen Xu, PhD
Executive Director
Amgen Neuroscience

 

> More about the product

Aimovig_logo
Eric_Pearlman_Eli_Lilly__BioTech_Web_1_Pharna_Web_1

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company

 

> More about the product

Emgality_logo
Dan_Cua_Janssen_BioTech_Web_1

Dan Cua, PhD
Vice President
IL-23 Pathway Area Leader for the Immunology Therapeutic Area
Janssen Biotech, Inc.

 

> More about the product

Tremfya_logo
Mads_Frederik_Rasmunssen_Novo_Nordisk_BioTech_Web_1

Dr. Mads Frederik Rasmussen
Corporate Project Vice President (CPVP) for GLP-1, CV and Outcomes
Novo Nordisk A/S

 

> More about the product

Rybelsus_logo
Marcie_Ruddy_Regeneron_BioTech_Web_1

Marcella Ruddy
Vice President, Strategic Program Direction, Immunology and Inflammation
Regeneron

 

> More about the product

Dupixent_logo

2

12:00 pm – 1:15 pm ET

Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions?

Category: Cancer, other rare conditions and vaccines

Moderator:
Michael Ringel, JD PhD 

Managing Director and Senior Partner
BCG

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Javad_Shahidi_Daiichi_BioTech_Web_2

Javad Shahidi, MD, MSc
Vice President, Global Oncology R&D
Daiichi Sankyo

 

> More about the product

Enhertu_logo
Beth_Ann_Coller_Ervebo_Biotech_Web_2

Beth-Ann Coller, PhD
Executive Director, Global Clinical Development
Merck & Co., Inc

 

> More about the product

Ervebo_logo
Flavio Manetlli

Flavio Manetlli, MD, PhD
Chief Medical officer
Dompé U.S. Inc.

 

> More about the product

Oxervate_logo
Dan_Sexton_Takeda_BioTech_Web_2

Dan Sexton
Strategy Lead
Takeda Pharmaceutical Company Limited

 

> More about the product

Bernard_Delaey_Sanofi_BioTech_Web_2

Bernard Delaey
Regulatory Therapeutic Area Lead
Sanofi

 

> More about the product

Cablivi_logo

3

1:30 pm – 2:45 pm ET

Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments?

Category: Rare Genetic Disorders

Tanya_Lewis_BioTech_Web_3_Chair

Moderator:
Tanya Lewis

Associate Editor for Health and Medicine
Scientific American

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Pushkal_Garg_Alnylam_BioTech_Web_3

Pushkal Garg, MD
Chief Medical Officer
Alnylam

 

> More about the product (GIVLAARI)

> More about the product (ONPATTRO®)

 

1594928706GIVLAARI_®_US_4C
Onpattro_logo
Jonathan Sorof

Jonathan Sorof, M.D.
Senior Vice President, Head of Medical Affairs
Global Blood Therapeutics

 

> More about the product

Oxbryta_logo
Dave Lennon

David J. Lennon (Dave)
President
Novartis Gene Therapies

 

> More about the product

Zolgensma_logo